PDCD1 and cancer: These above suggest that: 1 TMPRSS2 might be a new target for combined therapies based on anti-PD-1; 2This combined strategy may significantly extend cancer immunotherapy and improve the clinical benefits of male LUAD patients; 3 Among these, the advanced patients may profit more from the therapeutics above.